Simvastatin inhibits glucose metabolism and legumain activity in human myotubes.
Simvastatin, a HMG-CoA reductase inhibitor, is prescribed worldwide to patients with hypercholesterolemia. Although simvastatin is well tolerated, side effects like myotoxicity are reported. The mechanism for statin-induced myotoxicity is still poorly understood. Reports have suggested impaired mito...
Main Authors: | Robert Smith, Rigmor Solberg, Linn Løkken Jacobsen, Anette Larsen Voreland, Arild Christian Rustan, G Hege Thoresen, Harald Thidemann Johansen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3885717?pdf=render |
Similar Items
-
Correction: Simvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes
by: The Staff
Published: (2014-01-01) -
Correction: Simvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes.
Published: (2014-01-01) -
Nuclear legumain activity in colorectal cancer.
by: Mads H Haugen, et al.
Published: (2013-01-01) -
Correction: Nuclear Legumain Activity in Colorectal Cancer
by: Mads H. Haugen, et al.
Published: (2013-01-01) -
Correction: Nuclear Legumain Activity in Colorectal Cancer.
by: Mads H. Haugen, et al.
Published: (2013-01-01)